Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748144 | 1.00 | TP53 (0.32) | TP53TSHR | |
| SCHEMBL4748237 | 1.00 | TP53 (0.32) | TP53TSHR | |
| SCHEMBL29864586 | 0.81 | — | — | |
| SCHEMBL19284973 | 0.80 | BACE1 (0.32) | — | |
| SCHEMBL1804485 | 0.80 | DUT (0.32) | TP53TSHR | |
| SCHEMBL20522989 | 0.80 | BACE1 (0.32) | — | |
| SCHEMBL19284991 | 0.80 | BACE1 (0.32) | — | |
| SCHEMBL8076557 | 0.80 | — | — | |
| SCHEMBL15303946 | 0.79 | — | — | |
| SCHEMBL8527388 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
| WO-2023235809-A1 | CGAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-113943296-A | Pyrrolopyrimidine derivatives and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-7999090-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI CO., LTD (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7928209-B2 | reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA | EISAI R & D MANAGEMENT CO. LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7910712-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7897387-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20090325228-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-7541332-B2 | Fungal cell wall synthesis gene | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20090117586-A1 | FUNGAL CELL WALL SYNTHESIS GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7192980-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2007-03-20 | — | — | US | disclosed |
| US-7192980-B2 | Certain substituted polyketides, pharmaceutical compositions containing them and their use in treating tumors | NOVARTIS AG (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20060234283-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20060234349-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| US-20040038239-A1 | Fungal cell wall synthesis gene | EISAI CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1300464-A1 | FUNGAL CELL WALL SYNTHESIS GENE | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-4892961-A | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0210657-B1 | AMINO ACID DERIVATIVES, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988001619-A1 | 1'-METHYL-BETA-LACTAM COMPOUNDS AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-03-10 | — | — | WO | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325228-A1 | FUNGAL CELL WALL SYNTHESIS GENE | ERG28, GPI, DPM1 | TP53 4545/4885TSHR 4720/4885 |
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | TP53 59/4885TSHR 4560/4885 |
| US-20040038239-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | TP53 4545/4885TSHR 4720/4885 |
| US-20060234349-A1 | Fungal cell wall synthesis gene | ERG28, GPI, DPM1 | TP53 4545/4885TSHR 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.